A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia.

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs Monascus (Primary)
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors Beijing Peking University WBL Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2012 Planned End Date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov record.
    • 01 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top